Stock Analysis

Sichuan Biokin PharmaceuticalLtd Third Quarter 2024 Earnings: CN¥1.50 loss per share (vs CN¥0.46 loss in 3Q 2023)

SHSE:688506
Source: Shutterstock

Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥109.8m (up 65% from 3Q 2023).
  • Net loss: CN¥601.0m (loss widened by 222% from 3Q 2023).
  • CN¥1.50 loss per share (further deteriorated from CN¥0.46 loss in 3Q 2023).
earnings-and-revenue-growth
SHSE:688506 Earnings and Revenue Growth October 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sichuan Biokin PharmaceuticalLtd Earnings Insights

Looking ahead, revenue is expected to decline by 37% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in China are expected to grow by 13%.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 8.5% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Sichuan Biokin PharmaceuticalLtd (including 1 which doesn't sit too well with us).

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.